[Skip to Navigation]
Comment & Response
August 2017

Using Rho Kinase Inhibitors for Retinal Detachment—Reply

Author Affiliations
  • 1Nuffield Laboratory of Ophthalmology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, England
  • 2Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, England
  • 3Retinal Unit, Sydney Eye Hospital, Sydney NSW 2000, Australia
  • 4.Save Sight Institute, Discipline of Ophthalmology, University of Sydney, Sydney, Australia
  • 5Moorfields Eye Hospital, London, England
JAMA Ophthalmol. 2017;135(8):895-896. doi:10.1001/jamaophthalmol.2017.2283

In Reply We thank Townes-Anderson and colleagues for their insightful letter in response to our recent publication.1 Our work investigates changes in retinal structure, spatial vision, contrast detection/threshold sensitivity, color discrimination, and color matching following limited iatrogenic detachment of the macula in 5 consecutively treated men as a part of a phase I/II trial of gene therapy for choroideremia (NCT01461213). We demonstrated that retinal reattachment occurred within 1 week of the procedure and that best-corrected visual acuity recovered by 1 month in all 5 participants. One patient was observed to have altered color matching at all follow-up points and 2 demonstrated reductions in threshold sensitivity at 1 month.

Add or change institution